How long before the democrats sue to stay unhealthy and fat?

President Trump announced a major agreement today with Eli Lilly and Novo Nordisk to dramatically cut the cost of popular weight-loss drugs, specifically GLP-1 medications like Wegovy, Ozempic, Zepbound, and Mounjaro. Here are the key points:

Discounted Pricing:

Through a new government-backed platform called TrumpRx, injectable GLP-1 drugs will cost about $350 per month initially, dropping to $250 within two years for people paying out-of-pocket.
For Medicare and Medicaid patients, the negotiated price will be $245 per month, with a $50 copay for qualifying Medicare beneficiaries.
Future oral versions of these drugs (pending FDA approval) will start at $149 per month.

Coverage Expansion:

For the first time, Medicare will cover obesity drugs for patients with severe obesity (BMI > 35) and related conditions starting mid-2026.
Medicaid coverage will depend on state participation.

Broader Impact:

The agreement is part of Trump’s “Most Favored Nation” pricing policy, aiming to align U. S. drug prices with the lowest prices abroad.
The deal also includes discounts on other medications like insulin and migraine treatments.

TrumpRx Launch:

Expected to go live by early 2026, allowing Americans to buy drugs directly from manufacturers at negotiated prices without going through insurance.

How long before the democrats sue to stay unhealthy and fat?
Post Opinion